Moloney Securities Asset Management LLC Purchases New Shares in Certara, Inc. (NASDAQ:CERT)

Moloney Securities Asset Management LLC acquired a new position in shares of Certara, Inc. (NASDAQ:CERT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 12,000 shares of the company’s stock, valued at approximately $128,000.

Other institutional investors have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its holdings in Certara by 4.5% during the second quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after purchasing an additional 975 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Certara by 24.2% in the 3rd quarter. SG Americas Securities LLC now owns 20,260 shares of the company’s stock worth $237,000 after buying an additional 3,948 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Certara by 46.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 22,300 shares of the company’s stock worth $261,000 after buying an additional 7,100 shares during the last quarter. Kopion Asset Management LLC bought a new position in shares of Certara in the third quarter valued at approximately $4,457,000. Finally, Blue Trust Inc. increased its position in shares of Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after acquiring an additional 2,076 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Analyst Ratings Changes

CERT has been the subject of a number of recent analyst reports. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Barclays decreased their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Certara has an average rating of “Hold” and a consensus price target of $15.92.

Certara Stock Performance

Shares of CERT opened at $13.86 on Wednesday. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87. The stock’s 50-day simple moving average is $11.90 and its 200 day simple moving average is $11.70. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -69.30, a price-to-earnings-growth ratio of 9.33 and a beta of 1.57.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.